Key Highlights

  • The OneRF Ablation System, cleared by the FDA in December 2023, uses the same implanted sEEG electrode for both seizure mapping and temperature-controlled radiofrequency ablation, and NeuroOne is now layering on a second indication for facial pain.
  • Restated fiscal second-quarter 2026 results (quarter ended March 31, 2026) showed product revenue of $1.86 million and a net loss of $2.38 million, both worse than the company's original May 12, 2026 release after an invoicing error tied to a customer order change.
  • Cash of $2.8 million as of March 31, 2026, an accumulated deficit of roughly $82.4 million, and going-concern language mean the company is leaning on Zimmer Biomet minimum-purchase commitments and cost cuts to fund operations into fiscal 2026.
  • On May 22, 2026, NeuroOne disclosed it would restate its Form 10-Q for the quarter ended March 31, 2026, filed just ten days earlier.

NeuroOne Medical Technologies (NASDAQ:NMTC) markets the only FDA-cleared electrode platform that both records brain activity and delivers radiofrequency ablation through the same implanted device. Its OneRF system is expanding from epilepsy into facial pain, while a Zimmer Biomet distribution partnership drives sales. But a May 2026 revenue restatement, a 1-for-6 reverse split, and a going-concern warning complicate the growth story.

A Neurosurgery Platform Drawing Fresh Scrutiny

NeuroOne Medical Technologies Corporation (NMTC), an Eden Prairie, Minnesota-based medical device developer, has spent the past three years converting a diagnostic electrode business into a combination diagnostic-and-therapeutic platform aimed at epilepsy and, increasingly, chronic pain. Instead of implanting one set of electrodes to locate a seizure focus and then performing separate surgery to treat it, NeuroOne's technology lets the same thin-film electrode already placed for stereo-electroencephalography, or sEEG, monitoring subsequently deliver radiofrequency ablation.

That combination device, the OneRF Ablation System, received FDA 510(k) clearance on December 11, 2023, for creating radiofrequency lesions in nervous tissue for functional neurosurgical procedures, per the company's press release of that date filed with the SEC. It was NeuroOne's third FDA-cleared product family and first therapeutic device; a limited launch began March 26, 2024. In August 2025, NeuroOne added a fourth clearance, the OneRF Trigeminal Nerve Ablation System, cleared August 18, 2025 for procedures creating radiofrequency lesions to treat pain or lesion nerve tissue, opening a facial-pain indication it calls a new addressable market.

From Diagnostic Electrodes to a Four-Product FDA Portfolio

NeuroOne's older diagnostic products remain the base of its commercial business. The Evo sEEG Electrode received FDA 510(k) clearance on October 20, 2022, for temporary use of less than 30 days with recording, monitoring, and stimulation equipment at the subsurface level of the brain, the company's second cleared product behind its Evo Cortical Electrode line. Commercialization runs largely through Zimmer Biomet. Under an Amended and Restated Exclusive Development and Distribution Agreement dated October 25, 2024, Zimmer paid NeuroOne a $3.0 million upfront fee for an exclusive license to distribute the OneRF Ablation System in the brain, plus eligibility for a $1.0 million milestone payment NeuroOne's most recent filing says it does not expect to reach.

The license runs until October 31, 2034; Zimmer separately holds exclusive sEEG and strip/grid rights through September 30, 2032. The parties amended the arrangement again on December 31, 2025, tied to anticipated Zimmer minimum-purchase commitments. The Trigeminal system is not covered by Zimmer's license; NeuroOne is weighing direct sales versus a new partner.

Catalyst Analysis: NeuroOne (NMTC) Navigates a Restatement Alongside Its Clearance Milestones

The most consequential recent event for NMTC was accounting-related, not clinical. On May 22, 2026, NeuroOne disclosed it would restate its Form 10-Q for the quarter ended March 31, 2026, filed just ten days earlier. Management said a post-release review found a customer order modification on a shipment at quarter-end, after a customer questioned certain invoices; revenue and cost of product revenue had been recognized on invoices that should have been cancelled. The correction, filed as a 10-Q/A on June 12, 2026, cut fiscal second-quarter product revenue from $2.39 million to $1.86 million and deepened the net loss from $2.09 million to $2.38 million. Cash was unaffected, and NeuroOne reaffirmed guidance for at least $10.5 million of product revenue in fiscal 2026, up at least 17% from $9.1 million in fiscal 2025.

Latest Reported Quarter: Restated Fiscal Second-Quarter Results

NeuroOne's fiscal year ends September 30, making the quarter ended March 31, 2026 its fiscal second quarter. As restated, product revenue was $1,862,050, up from $1,386,550 a year earlier but below the $2,391,185 originally reported. Cost of product revenue was $871,786, leaving gross profit of $990,264, a margin of roughly 53%. There was no license revenue in the quarter; total operating expenses were $3.39 million, split between $1.92 million of selling, general and administrative costs and $1.47 million of research and development. The restated net loss was $2,382,022, or $0.28 per basic share, versus $2,270,607 a year earlier. For the first six months of fiscal 2026, product revenue was $4,754,685 and net loss was $3,819,912.

Revenue, Cash Position, Going Concern and Dilution

NeuroOne ended the quarter with $2,804,011 in cash, down from $6,570,382 at the start of the fiscal year, and an accumulated deficit of roughly $82.4 million. Its going-concern disclosure says recurring losses and negative operating cash flow raise substantial doubt about its ability to continue, and that it is relying on current cash, Zimmer minimum-purchase commitments, improving margins, and expense cuts to fund operations only into fiscal 2026. Dilution has been substantial: NeuroOne executed a 1-for-6 reverse split effective April 16, 2026, after shares outstanding swelled past 50 million, and it has drawn multiple Nasdaq minimum-bid-price deficiency notices since 2024. Post-split shares outstanding were 8,619,876 as of May 8, 2026, with an at-the-market program, expanded to $6.75 million in August 2025, still available.

Growth Opportunities and Upcoming Milestones

Beyond the Trigeminal system's early rollout, NeuroOne is pursuing a Basivertebral Nerve Ablation System, a percutaneous paddle lead for spinal cord stimulation targeting lower back pain, and a drug delivery system it hopes will be ready for investigational or animal studies in its fiscal third quarter. It also cited progress toward ISO 13485 certification for distribution outside the United States and a post-market patient registry for the brain OneRF system.

Material Risks Specific to NeuroOne

The restatement is a red flag on internal controls; management says it will keep strengthening financial reporting. Going-concern language, a thin cash cushion, heavy reliance on Zimmer Biomet for distribution, and a history of dilutive raises and reverse splits all weigh on the equity story. NeuroOne does not expect to reach the additional $1.0 million Zimmer milestone, and the Trigeminal system's commercial path outside Zimmer remains undefined.

Outlook

In an upside scenario, continued OneRF adoption in epilepsy centers, successful expansion into facial pain, and a partner for newer pain programs could let NeuroOne hit or exceed its $10.5 million fiscal 2026 revenue guidance while margins hold near the mid-50% range already reported. In a base case, the company muddles through on Zimmer's reach and cost discipline, extending its runway modestly while still posting losses. In a downside case, going-concern doubts intensify, additional dilutive financing or another reverse split becomes necessary, and Nasdaq compliance again becomes a live issue. No price target or return outcome can be inferred from these scenarios.

Conclusion

NeuroOne Medical Technologies Corporation (NMTC) has built a differentiated combination electrode platform, anchored by the OneRF Ablation System's ability to record and ablate through the same implanted device, and keeps adding indications and cleared products. Whether that clinical edge translates into durable financial stability depends on execution against a tight cash position, a recently disclosed restatement, and the pace of Zimmer Biomet-driven commercialization ahead.

This article is for informational purposes only and does not constitute investment advice or a recommendation to buy, sell, or hold any security. Share prices can rise or fall, and past performance does not guarantee future results. Investors should conduct independent research and consult a licensed financial adviser before making investment decisions.